Magnifi Communities

Last week, the market was finally able to break out of the restraints of the range it had been bounded to with the first meaningful move in quite sometime. Led by mostly big tech stocks to begin with as evidenced by an almost parabolic surge in the Nasdaq (NDX), many other sectors are beginning to follow their lead. This surge has also led to a fair amount of FOMO by investors and traders who doubted the initial validity of the rally, lending more momentum to the move.
As for the S&P 500 (SPX), the coveted 4200 mark has been surmounted, signaling to many market participants that this rally is very much underway. Even with the inevitable pullback that often follows such a move higher, this level should remain a strong support level.
With debt ceiling talks continuing, much of this rally has taken place in anticipation of a deal being reached, however, the hopes of one being reached by the end of last week quickly fizzled out. Now, the chances of a deal being reached before default have seemingly gone down the drain with neither side looking to budge on their proposed demands.
This will indeed continue to have a fair amount of influence on where the market goes next, whether it pushes higher on a “buy the rumor” scenario or if the default will finally be what knocks the market off its trajectory.
In the meantime, keep an eye on the key levels I highlight below in order to map out the market’s next possible move.
[embedded content]
Join my Smart Trades options trading service today to see exactly how my students and I trade these types of scenarios! Smart Trades is where I teach my students how I trade options on some of the largest ETFs on the exchange. As you learn, you’ll get exclusive access to all my trades with notifications any time one is put on. Now, you can learn how many use this high-income skill to achieve financial freedom. Join today!
Good Luck With Your Trading!
Christian Tharp, CMT

When it comes to the debt ceiling, there’s a good deal of negativity. However, we are seeing some breaks in the clouds. For example, House Speaker Kevin McCarthy says he doesn’t think the U.S. will default on its debt.
“I think at the end of the day we do not have a debt default,” McCarthy told CNBC.
Also, as noted by NBC News:
“Leaving the meeting, congressional leaders hinted at some progress. McCarthy, (R)-Calif., said that the sides remain ‘far apart’ but that ‘it is possible to get a deal by the end of the week.’”
If a deal is put in place later this week, markets could see an explosive relief rally.
So, what’s the best way to prepare for this possibility? One way is to pick up index ETFs, such as SPDR Dow Jones Industrial Average ETF Trust (DIA). Last trading at around $330, it wouldn’t be all that shocking to see the DIA ETF recover to $342.50 on a recovery rally.

The DIA ETF tries to provide results that mirror the performance of the Dow Jones Industrial Average. Some of its top holdings include Goldman Sachs (GS), Microsoft (MSFT), McDonald’s (MCD), and several more giant companies from various sectors and industries. In short, the DIA ETF allows you to trade alongside the DJIA and gain exposure to some of the most solid stocks in the market.
Next we have the tech-heavy Invesco QQQ Trust Series 1 ETF (QQQ), which was last trading just north of $330, and with an expense ratio of 0.2%, it’s not all that expensive to add to your long-term portfolio. The ETF is made up of 100 holdings with the focus of tracking the NASDAQ-100 Index.
This means some of its top positions include stocks like Microsoft (MSFT), Apple (AAPL), Amazon (AMZN), NVIDIA (NVDA), Meta (META), Alphabet (GOOGL), and Tesla (TSLA) all stocks that have been leading the charge during this market rally.

The final fund we want to examine when trying to find a way to cast a wide net and hitch a ride to what could end up being the next leg of this bull market, the popular SPDR S&P 500 ETF Trust (SPY), whichprovides investment results that, before expenses, correspond generally to the price and yield performance of the S&P 500. Some of its top holdings mirror much of the Q’s ETF. Stocks like Apple (AAPL), Microsoft (MSFT), Amazon (AMZN), NVIDIA (NVDA), Alphabet (GOOGL), and Tesla (TSLA).

All three of these ETFs could potentially rally higher on a conclusion of the debt ceiling chaos and seeing to it that your portfolio balance surges with it.
Think Discovering New Ways To Invest Is All Magnifi Has To Offer? Think Again…
With your new AI-powered investing mentor, you now have a co-pilot to help you along your investment journey. Tell Magnifi to add your favorite stocks to your watchlist and boom, it’s done.
You can even take your analysis a step further using Magnifi, which allows you to compare funds like these to each other, allowing you to determine which is right for your portfolio.
The above links are what you can use to get FULL VIP ACCESS to All Star Funds content where we go further down the investing rabbit hole, as well as showing you how to use the AI investing tool Magnifi, the first of its kind.
Once you sign up, the power of this tool will be apparent and you will wonder why you ever went through your investment journey without an AI co-pilot. Join today and thank yourself tomorrow!

Last week, Options360 established a bullish option position in SPDR Biotech ETF (XBI), based on both fundamental and technical reasons.
However, yesterday there was a ruling by the Federal Trade Commission that has cast a cloud over the sector causing me to re-think whether to maintain the position. I thought it might be helpful to share my process for not just initiating the trade, but also how I evaluate and manage the position through changes in time, price, and profit potential.
I have a feeling my final decision on whether to stick with the trade will be of the order of the old John Maynard Keynes quote, “When the facts change, I change my mind.”
First, let me share my reasoning for establishing the bullish position; here is part of the alert sent to Options360 members on May 9, when XBI was trading $84 per share.
“XBI is near equal weight (largest holding is just 1.3%) of small cap biotech companies. Most are not profitable but many have promising pipelines.
These firms (and biotech/healthcare) are fairly recession proof.
The larger pharma companies are always looking for acquisitions and usually willing to pay big premiums to fill their own often aging/coming off patent pipeline. And there has been a noticeable pick up in deals over the past few months.
Chartwise it has been in a decent uptrend and recently cleared resistance above $84. If this nascent bull flag can create a push above $86 and think a target of $90 looks possible.
I will use $83.25 as stop loss level.”
The chart below shows the $83-84 support level and the formation of a potential bull flag.

The recommended trade was to buy a July 86 call. On Monday, the stock rallied above $88 and we sold a short-term 91 call to leg into a diagonal at an advantageous price. Things looked good.
Let me backup, before I get to today’s dilemma.
One of the many attractions of Exchange-Traded Funds (ETFs) is their reduction of single stock risk; if one company has bad news or fails to execute its shortcomings, the decline won’t sink your entire position.
This makes using a sector ETF, especially for industries in which there can be a wide variety of outcomes, such as the biotech industry, a wise move in terms of risk management. Let’s face it, unless you’re an expert in the field, it is nearly impossible to keep up with all the research, progress, and potential applications for the drugs and treatments in development.
Using an ETF, which holds a basket of biotech stocks, some of which will fail and some that will achieve great success, is a time and financially efficient way to gain exposure for the sector.
So, much to my chagrin, XBI gapped down by some 3% on Tuesday in the wake of the FTC’s block of a proposed $28 billion acquisition of Horizon Therapeutics (HZNP) by Amgen (AMGN), causing shares of HZNP to plunge 23%.
This was a deal that was not supposed to have any trouble being approved. There was no overlap that would create less competition, and yet, it was blocked.
The drug/biotech industry is built on a model of small, often university and government-funded projects doing the initial research, hoping to develop a drug that can move towards Phase I testing.
If it passes muster then big pharma starts sniffing around to pick up the mantle, both financially and operationally, to get to Phase II and III, and ultimately, distribution.
This decision by the FTC (let’s face it, it’s an anti-business administration with an acute sense of the real need to reign in drug and healthcare costs) might have the unintended consequence of stifling innovation and development of medical breakthroughs if there is no path to continued financing, distribution, and profits.
If the regulatory environment changes in that acquisitions will be blocked the complexion of the whole industry changes.
Bringing us back to the trade. XBI dipped to $83.65, just above my stop loss trigger, before bouncing back above $85.
This morning I took another roll to collect premium and bring cost basis/risk down. This flexibility of options allows us to make adjustments to a more nuanced position. I’m staying with a more moderate bullish position and will be sticking with my stop to manage risk.
If you find yourself interested in learning more about me and my method of teaching even the most novice traders how to trade options, check out this presentation I put together to get filled in this link will take you directly to my Options360 presentation.
If you’re interested in joining Options360 and get in on all the action, you can follow this link to get signed up today!